Personalizing Insulin Delivery
For Patients with Diabetes

About Us


Diatech Diabetes, Inc. implements innovative solutions to empower the lives of patients, families, and communities impacted by diabetes.

Diatech originated from the issues our CEO was facing with his own diabetes care technology. Those who are affected by diabetes inspire us to work endlessly towards optimizing therapies for patients worldwide.

SmartFusion

Diatech is developing SmartFusion: a system for insulin pumps that monitors insulin delivery for accuracy and infusion set failure. SmartFusion's software could be integrated into an insulin pump or app and use data from the pump, continuous glucose monitor, and patient infusion habits to monitor the success of daily insulin dosages.

Our Goals

Diatech is committed to creating innovative solutions that empower the lives of patients, families, and communities impacted by diabetes. Our goal is to improve how systems monitor for complications and make devices more personalized to your needs.

Insulin infusions are administered through subcutaneous tissue injections to counteract a buildup of glucose in the blood throughout day.
Repeated insertions and chronic insulin exposure compromises the small volumes of subcutaneous tissue under the skin into which patients inject their syringes, pens and infusion set cannulas.
The changes in subcutaneous tissue can lead to infusion site abnormalities, which could reduce the efficacy of the insulin being used and lead to hazardous consequences to those living with this diabetes.

A successful infusion has insulin being deposited into the subcutaneous layer where it gets absorbed into the bloodstream via the blood vessels in the tissue.

An infusion site leak can happen if the cannula has been improperly inserted or if the injection site has been damaged during normal use. A leak can happen when a child sweats causing the infusion site to become loose, resulting in an underdelivery of medication.

An infusion site blockage can happen if the cannula is injected into damaged skin tissue or kinks during a faulty insertion. Blockages may produce a build up of insulin that could release into the body resulting in an overdose of insulin.

An infusion site dislodgement is when the cannula comes loose/gets removed from the site of injection. Dislodgements cause the adhesive pad to unstick from the injection site and severely alter the integrity of the injected cannula.

Not all skin tissue is the same, and not everyone can tell if they are injecting into damaged skin tissue or a “bad site”. Lack of proper rotation can cause inflammation at the site and increase the likelihood of developing scar tissue.

>80%
of Insulin pump users experience infusion malfunctions that may lead to insulin delivery failure

1.5-24hrs
How long current systems can take for detection of infusion malfunctions

1M+
Patients worldwide who use insulin pumps

$3.9B
Value of global insulin pump market (expected growth to $6.9B by 2026)